5-Bottles-Box-15533-FOur MagCloudz™ Cell Separation products use magnetic particles as a carrier for our proprietary QuickGel™ technology, which enables target cell capture via a familiar magnetic cell isolation workflow. At the end of the cell separation process, using the Q-Mag or comparable magnetic stand, the MagCloudz™ are dissolved in less than one minute, using a biologically friendly buffer.

This releases the target cells from the magnetic carriers, leaving the captured cells behind in their native state after removal of the magnetic particles. Our unique cell release capabilities drastically increase cell viability compared to conventional magnetic separation products and eliminate retained magnetic labels from isolated cell populations.

Quad Approach figure


Conventional Approach figure


MagCloudz™ Cell Separation kits have been successfully used in a number of applications. Here, we present representative data highlighting KG-1a purification and enrichment from peripheral blood mononuclear cell (PBMC) fractions is shown in the figure below:

Representative KG1 data_Products Page

Representative flow cytometry dot plots for T-Cell enrichment and purification from peripheral blood. Cell populations were stained with PerCP-conjugated anti-CD3, PE-conjugated anti-CD45, annexin-V-FITC (apoptosis marker) and propidium iodide (viability marker) following the MagCloudz Streptavidin cell separation protocol. A total of 80% of the target T-Cell population was recovered as magnetic label-free T-Cells from the MagCloudz Streptavidin in this assay.

 A) The forward and side-scatter profile of the initial PBMC population;

B) 56% CD3+/CD45+ T-Cells (target cell population) were present in the initial sample;

C) 92% T-Cell uptake as indicated by the low percentage of T-Cells remaining in the un-bound cell fraction following MagCloudz Streptavidin binding;

D) Forward and side-scatter profile of the recovered CD3+ T-Cell population;

E) High purity T-Cells were recovered from the MagCloudz Streptavidin, enriched from 56% in the initial population to 98% in the final isolated/released population and

F) High viability (99%) of the recovered T-Cells, indicated by the absence of annexin-V and propidium iodide staining in the bottom left quadrant of the plot.